Dessight Microsurgical Robot

Dessight’s Microsurgical Robot extends the company’s precision platform beyond ophthalmology into broader supermicrosurgical applications. Featuring approximately 20 degrees of freedom and sub-millimeter anastomosis capability, the system completed the world’s first robot-assisted lymphatic-venous anastomosis for Alzheimer’s disease treatment in January 2025.

Product Overview

Building on core technologies developed for ophthalmic surgery, this platform addresses supermicrosurgical procedures requiring manipulation of structures between 0.3-0.8mm in diameter. Such procedures exceed the precision limits of human hands unaided by robotic assistance, limiting access for many patients and requiring highly specialized surgical expertise.

The system provides stable, precise control for procedures across multiple specialties including plastic surgery, neurosurgery, otolaryngology, and vascular surgery where microsurgical technique is critical to outcomes.

Key Features

High Degree-of-Freedom Design: Approximately 20 articulated joints enable complex manipulation patterns required for delicate tissue handling and suturing at supermicroscopic scales.

Sub-Millimeter Precision: The system achieves 0.1mm (100-micron) precision for anastomosis procedures, enabling reliable connection of vessels, lymphatics, and nerves in the 0.3-0.8mm diameter range.

Flexible Grasping Technology: Proprietary miniaturized wrist-type instruments and flexible grasping mechanisms enable stable tissue manipulation without damage.

Tremor Filtration: Motion scaling and tremor compensation extend surgeon capability beyond physiological limitations during extended procedures.

Technical Specifications

Designed for vessels 0.3–0.8mm in diameter, Dessight’s microsurgical robot provides approximately 20 degrees of freedom with 0.1mm anastomosis precision, enabling LVA and nerve-repair procedures beyond unaided human capability.

Clinical Applications

Lymphatic Surgery: Robot-assisted lymphatic-venous anastomosis (LVA) addresses lymphedema, a condition affecting millions of patients following cancer treatment or other lymphatic system damage. Traditional manual LVA requires exceptional surgical skill and is available at limited centers.

Neurosurgery: Nerve repair and anastomosis procedures benefit from robotic precision, particularly for small-caliber peripheral nerve reconstruction.

Reconstructive Surgery: Microvascular free flap procedures and tissue transfer surgeries requiring reliable small-vessel anastomosis represent key applications.

Otolaryngology: The system addresses complex reconstructive and functional procedures requiring microsurgical technique in confined anatomical spaces.

Clinical Validation

World’s First Robot-Assisted LVA for Alzheimer’s Treatment (January 2025): Performed at Zhejiang Provincial People’s Hospital, this procedure demonstrated the platform’s capability for cervical deep lymphatic-venous anastomosis, a procedure hypothesized to improve brain waste clearance in neurodegenerative disease.

China’s First Robot-Assisted Lymphedema Reconstruction (January 2025): The system completed a successful LVA reconstruction procedure for a lymphedema patient, achieving 0.2mm precision lymphatic-venous anastomosis. Coverage in People’s Daily highlighted the clinical significance.

The company reports deployment across dozens of hospitals with hundreds of patients treated using the combined ophthalmic and microsurgical platforms.

Regulatory Status

The microsurgical platform is in registration clinical trials. The company’s Series A funding (2025) specifically targets acceleration of clinical development for this product line.

Competitive Landscape

Globally, only two microsurgical robot systems have achieved CE certification: the Symani system from Medical Microinstruments (Italy) and the MUSA system from Microsure (Netherlands). Dessight’s platform represents the leading Chinese entry in this emerging category, with a differentiated technical approach based on flexible mechanism design.

Frequently Asked Questions

What distinguishes microsurgery from standard surgical procedures?

Microsurgery involves procedures on anatomical structures below 1mm in diameter, requiring specialized training, instrumentation, and visualization. Supermicrosurgery extends this to structures below 0.5mm, where human physiological limitations significantly impact outcomes. Robotic assistance addresses these limitations.

What conditions does this robot treat?

Primary applications include lymphedema (chronic swelling from lymphatic damage), nerve injuries requiring microscopic repair, and vascular reconstructions involving small-caliber vessels. The Alzheimer’s treatment application represents an emerging investigational use targeting brain lymphatic drainage.

How does robotic assistance improve microsurgical outcomes?

By filtering hand tremor and providing scaled precision, the robot enables reliable anastomosis of vessels as small as 0.3mm diameter—a task challenging for even highly skilled surgeons without assistance. This potentially expands treatment access and improves consistency across different surgeons and cases.

When will this product be commercially available?

The microsurgical platform is in clinical trials as of early 2026. Commercial availability timeline depends on registration trial completion and regulatory review progression.